Cannabichromene COVID-19 ARDS Treatment Patent Application
Summary
The USPTO published patent application US20260097051A1 from Augusta University Research Institute claiming compositions comprising Cannabichromene (CBC) for treating COVID-19 ARDS. The application was filed August 18, 2025 and published April 9, 2026.
What changed
The USPTO published patent application US20260097051A1 from Augusta University Research Institute claiming compositions comprising Cannabichromene (CBC) for treating acute respiratory distress syndrome (ARDS) and COVID-19 infection. The application was filed August 18, 2025 and published April 9, 2026.
Pharmaceutical companies and researchers developing CBC-based therapeutics should review the patent claims for freedom-to-operate and consider potential licensing or partnership opportunities with the assignee. While the application remains pending, the published claims provide notice of the intended IP scope.
What to do next
- Review patent claims for freedom-to-operate assessment
- Monitor patent prosecution status
Archived snapshot
Apr 10, 2026GovPing captured this document from the original source. If the source has since changed or been removed, this is the text as it existed at that time.
CANNABICHROMENE AS A THERAPEUTIC MODALITY FOR COVID-19
Application US20260097051A1 Kind: A1 Apr 09, 2026
Assignee
AUGUSTA UNIVERSITY RESEARCH INSTITUTE, INC.
Inventors
Babak BABAN, Krishnan DHANDAPANI, Jack YU
Abstract
Compositions and methods for treating or reducing symptoms of acute respiratory distress syndrome (ARDS) generally and COVID-19 infection, in particular, are provided. An exemplary method includes administering to the subject an effective amount of cannabichromene to reduce acute respiratory distress caused by ARDS generally and COVID-19 infection, in particular.
CPC Classifications
A61K 31/658 A61K 9/0073 A61P 29/00 A61P 31/14
Filing Date
2025-08-18
Application No.
19303075
Related changes
Get daily alerts for USPTO Patent Applications - Pharma (A61K)
Daily digest delivered to your inbox.
Free. Unsubscribe anytime.
Source
About this page
Every important government, regulator, and court update from around the world. One place. Real-time. Free. Our mission
Source document text, dates, docket IDs, and authority are extracted directly from USPTO.
The plain-English summary, classification, and "what to do next" steps are AI-generated from the original text. Cite the source document, not the AI analysis.
Classification
Who this affects
Taxonomy
Browse Categories
Get alerts for this source
We'll email you when USPTO Patent Applications - Pharma (A61K) publishes new changes.